Kolexia
Ianotto Jean-Christophe Hématologie
Ianotto Jean-Christophe
Hématologie
Hôpital Morvan
Brest, France
217 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Thrombocytémie essentielle Syndromes myéloprolifératifs Myélofibrose primitive Thrombocytose Thrombose Leucémies Polyglobulie primitive essentielle Polyglobulie Leucémie myéloïde

Collaborateurs

Voir plus
Lippert Eric
Lippert Eric
Hôpital Cavale Blanche, Brest, France
Kiladjian Jean-Jacques
Kiladjian Jean-Jacques
Hôpital Saint-Louis, Paris, France
Berthou Christian
Berthou Christian
Hôpital Morvan, Brest, France
Boyer Francoise
Boyer Francoise
Hôpital Larrey Angers, Angers, France

Industries

Voir plus
Novartis
38 collaboration(s)
Dernière en 2023
Abbvie
6 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2022
Pfizer
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System: Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Essai Clinique (CHU Poitiers)   19 mars 2024
Thrombocytémie essentielle et polyglobulie de Vaquez de l’enfant, de l’adolescent et du jeune adulte
Edimark   28 février 2024
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
American journal of hematology   25 février 2024
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
Haematologica   08 février 2024
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Leukemia   27 décembre 2023
Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera
65th ASH Annual Meeting Abstracts   02 novembre 2023
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
CDKN2C Deletion on 1p32 Locus As Part of Irwazh Score, a New Risk Assessment Model for Venous Thromboembolism Occurring within 6-12 Months of Treatment Initiation in Newly Diagnosed Multiple Myeloma
65th ASH Annual Meeting Abstracts   02 novembre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023